

 SENDERRA <i>Specialty Pharmacy</i> 3712 E. Plano Parkway, Ste. 200 Plano, TX 75074 <i>This prescription form is to be sent & received via fax</i>	Pediatric Atopic Dermatitis Enrollment Form A-H Physician Offices Call: 855-460-7928 Fax: 888-777-5645	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2">Prescriber:</td> <td>NPI:</td> </tr> <tr> <td colspan="2">Supervising Physician:</td> <td>NPI:</td> </tr> <tr> <td colspan="2">Address:</td> <td>Tax ID:</td> </tr> <tr> <td>Phone:</td> <td colspan="2">Fax:</td> </tr> <tr> <td colspan="3">Contact:</td> </tr> </table>	Prescriber:		NPI:	Supervising Physician:		NPI:	Address:		Tax ID:	Phone:	Fax:		Contact:		
	Prescriber:		NPI:														
	Supervising Physician:		NPI:														
	Address:		Tax ID:														
	Phone:	Fax:															
Contact:																	

PATIENT INFORMATION

Name:	☐ M ☐ F ☐ Trans M ☐ Trans F ☐ Other	DOB: ____/____/____	SS#: ____-____-____
Street:	City:	State: ____	ZIP: ____-____
Phone:	Alt. Phone:	☐ English ☐ Spanish ☐ Other: ____	Wt.: ____ Ht.: ____


PRESCRIPTION

Has the patient received a loading dose/starter kit? ☐ Yes Start Date: ____/____/____ ☐ No SHIP TO: ☐ Patient's Home ☐ Doctor's Office ☐ Other: ____				
Drug	Directions & Quantity	Refills		
Adbry® ☐ 150 mg Pre-filled Syringe*	☐ INITIAL: Inject 300 mg (two 150 mg injections) SQ at day 1 (Quantity: 2) ☐ MAINTENANCE: Inject 150 mg SQ every other week starting at day 15 (Quantity: 2)			
	Cibinqo® ☐ 100 mg Tablet* ☐ 200 mg Tablet*	☐ Take 100 mg PO once daily (Quantity: 30) ☐ Take 200 mg PO once daily (Quantity: 30) ***Intended for patients who have not achieved adequate response with 100 mg daily dose*** ***WEIGHT REQUIRED*** ____		
Dupixent® ☐ 300 mg Pre-filled Syringe ☐ 300 mg Pen* ☐ 200 mg Pre-filled Syringe ☐ 200 mg Pen*	☐ Inject 300 mg SQ every 4 weeks (Quantity: 2) ***Intended for patients age 6 months to 5 years old weight 15 kg/33 lbs to <30 kg/66 lbs*** ☐ INITIAL: Inject 600 mg SQ at day 1 (Quantity: 2) ☐ MAINTENANCE: Inject 300 mg SQ every 4 weeks starting at day 29 (Quantity: 2) ***Intended for patients age 6 years to 17 years old weight 15 kg/33 lbs to <30 kg/66 lbs*** ☐ INITIAL: Inject 600 mg SQ at day 1 (Quantity: 2) ☐ MAINTENANCE: Inject 300 mg SQ every other week starting at day 15 (Quantity: 2) ***Intended for weight ≥ 60 kg/132 lbs***			
	☐ Inject 200 mg SQ every 4 weeks (Quantity: 2) ***Intended for patients age 6 months to 5 years old weight 5 kg/11 lbs to <15 kg/33 lbs*** ☐ INITIAL: Inject 400 mg SQ at day 1 (Quantity: 2) ☐ MAINTENANCE: Inject 200 mg SQ every other week starting at day 15 (Quantity: 2) ***Intended for weight 30 kg/66 lbs to < 60 kg/132 lbs***			
	Ebglyss® ☐ 250 mg Pre-filled Syringe ☐ 250 mg Pen	☐ INITIAL: Inject 500 mg (two 250 mg injections) SQ at week 0 & week 2 (Quantity: 4) ☐ INDUCTION: Inject 250 mg SQ every 2 weeks starting at week 4 (weeks 4-14) (Quantity: 2 plus 2 refills) ☐ MAINTENANCE: Inject 250 mg SQ every 4 weeks thereafter starting at week 16 (Quantity: 1) ☐ MAINTENANCE: Inject 250 mg SQ every 8 weeks thereafter starting at week 16 (Quantity: 1) ***WEIGHT REQUIRED*** ____ ***Intended for patients age 12 years and older weighing ≥ 40 kg/88 lbs***		
	Eucrisa® ☐ 2% Ointment 60 gm* ☐ 2% Ointment 100 gm*	☐ Apply a thin layer to affected area(s) twice a day (Quantity: 1 tube)		

*Adbry/Dupixent pens/Cibinqo/Ebglyss FDA approved for ages 12 and older

*Eucrisa FDA approved for ages 3 months and older

MEDICAL INFORMATION

PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY					
PREVIOUS THERAPIES: ☐ Methotrexate ☐ Cyclosporine ☐ Tacrolimus ☐ Elidel ☐ Protopic ☐	Tried & Failed (Duration): ☐ (____) ☐ (____) ☐ (____) ☐ (____) ☐ (____) ☐ (____)	Not Tolerated: ☐ ☐ ☐ ☐ ☐ ☐	Contraindication: _____ _____ _____ _____ _____ _____	 ☐ Face ☐ Feet ☐ Groin ☐ Hands ☐ Nails ☐ Scalp ☐ Other: Scoring tool used ☐ BSA ☐ EASI ☐ ISGA ☐ POEM ☐ SCORAD % or Score: ____ Allergies:	
PHOTOTHERAPY ☐ UVA /UVB ☐ Patient cannot afford	Tried & Failed (Duration): ☐ (____)	Not Tolerated: ☐	Contraindication: _____ ☐ Risk of Skin Cancer ☐ Distance from Office		
☐ L20.9 Atopic Dermatitis ☐ (Mild to Moderate) ☐ (Moderate to Severe) ☐ Other: _____ Date of Diagnosis: ____/____/____					
Active TB is ruled out: ☐ Yes ☐ No Date: ____/____/____ Hep B ruled out/treated: ☐ Yes ☐ No Date: ____/____/____					

Additional Clinical Information:

INJECTION TRAINING

☐ Patient has received pen and injection training ☐ Physician's office to provide injection training ☐ Senderra to coordinate injection training

PRESCRIBER SIGNATURE

To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations. Prescriber: _____	Date: ____/____/____
---	-----------------------------

CONFIDENTIALITY NOTICE

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.